Related Experiment Video

Updated: Jun 10, 2026

An Ex vivo Model to Study Hormone Action in the Human Breast
12:31

An Ex vivo Model to Study Hormone Action in the Human Breast

Published on: January 8, 2015

Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo

Yi Chen1, Edwin A Alvarez, Diana Azzam

  • 1Braman Family Breast Cancer Institute, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, 33136, USA. ychen@jding.dhs.org

Breast Cancer Research and Treatment
|July 30, 2010
PubMed

Insights

Combining Src inhibitor saracatinib with antiestrogen therapy enhances breast cancer cell cycle arrest and delays resistance. This combination therapy, targeting both estrogen receptor and Src pathways, shows promise for ER-positive breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Estrogen receptor (ER)-positive breast cancers are often treated with antiestrogen therapies that increase p27 to arrest cancer cell growth.
  • Src activation, found in up to 40% of ER-positive cancers, can promote p27 degradation, potentially leading to antiestrogen resistance.
  • Understanding the interplay between Src, p27, and antiestrogen therapy is crucial for overcoming treatment resistance.

Purpose of the Study:

  • To investigate the efficacy of combining the Src inhibitor saracatinib with ER-blocking drugs in treating ER-positive breast cancer.
  • To determine if combined inhibition of ER and Src can overcome or delay the development of drug resistance.
  • To identify molecular mechanisms, such as pathway activation, that contribute to drug resistance.

Main Methods:

  • Treatment of ER-positive breast cancer cells and MDA-MB-361 xenografts with saracatinib, fulvestrant, or combination therapy.
  • Assessment of cell cycle arrest via p27 levels and proliferation marker Ki67.
  • In vivo tumor growth inhibition studies.
  • Proteomic analysis of drug-resistant tumors and long-term cultured cell lines to identify resistance mechanisms.

Main Results:

  • Combined treatment with saracatinib and fulvestrant significantly increased p27, reduced Ki67, and impaired tumor growth compared to monotherapy.
  • Saracatinib monotherapy led to rapid development of drug resistance.
  • Proteomic analysis revealed bypass activation of the mTOR pathway in saracatinib-resistant tumors.
  • mTORC1 activation was also observed in ER-positive breast cancer cells cultured long-term with saracatinib.

Conclusions:

  • Combined inhibition of ER and Src with saracatinib and fulvestrant demonstrates enhanced efficacy and delays resistance in ER-positive breast cancer models.
  • The mTOR pathway represents a key bypass mechanism conferring resistance to saracatinib.
  • Further clinical investigation of saracatinib in combination with fulvestrant is warranted for ER-positive breast cancer.
  • Co-targeting mTOR with saracatinib may offer a more effective therapeutic strategy to overcome drug resistance.

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...